The development of a novel, sensitive enzyme-linked immunoassay (ELISA) for the detection of human lipocortin 1 [ I ] has enabled examination of the corticosteroid inducibility of this protein. Lipocortin 1 (molecular mass 37 kDa) has recently been the subject of intense investigation to substantiate early claims that it mediates the anti-inflammatory effects of corticosteroids by antagonising the activity of phospholipase A,. Although it has clearly been shown to have phospholipase A, inhibitory activity in vitro [2, 31, it remains uncertain whether this is a direct enzyme inhibition or due to an interaction with substrate [4]. Recombinant lipocortin 1 has recently been shown to mimic the effect of corticosteroid on carrageenan-induced paw oedema in rats IS], but there is no direct evidence that the protein can be induced in vivo by corticosteroid in man, although the promoter region of the DNA sequence does possess potential corticosteroid receptor binding sites [6].
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A bolus 100 mg intravenous dose of hydrocortisone was given to eight healthy male volunteers (median age 35 years) in an attempt to monitor changes in lipocortin 1 levels in peripheral blood leucocytes. Each experiment was begun at 13:OO h to correspond with the daily trough of endogenous circulating cortisol. Heparinized blood samples were taken before steroid administration and frequently over the course of the ensuing 240 min. As a control, an identical procedure was carried out on two subjects, the steroid infusion being replaced by placebo.
Leucocytes were separated by flotation on a FicollHypaque M-85 [ 5 1% (w/v) meglumine diatrizoate, 26% (w/ v ) sodium diatrizoate gradient. Plasma was also collected and Abbreviations used: ELISA, enzyme-linked immunoassay; MNC. mononuclear leucocytes; PMN, polymorphonuclear leucocytes. stored. Isolated mononuclear (MNC) and polymorphonuclear (PMN) leucocytes were washed in phosphatebuffered saline containing 1 mM-EDTA to release membrane-bound lipocortin 1. Washings were frozen and stored, as were the supernatants obtained when cells were freeze-fractured to release intracellular lipocortin 1 into phosphate-buffered saline with I mM-EDTA.
Lipocortin 1 levels in all collected fractions were assayed using a sensitive 'sandwich' ELlSA capable of detecting down to 500 pg/ml. Briefly, wells of microtitre plates coated with monoclonal antibody to human lipocortin 1 (a generous gift from Dr. J. L. Browning, Biogen, Massachusetts, U.S.A.) were used in reaction with plasma or supernatants of cell fractions. Bound lipocortin was detected with a polyclonal anti-lipocortin antibody (842, Biogen), followed by an antirabbit IgG conjugated to alkaline phosphatase. The colour reaction with p-nitrophenyl phosphate substrate was read at 405 nm on an automated plate reader and related to a standard curve of recombinant human lipocortin 1 [ 11.
Differential white cell counts were performed on each sample, allowing results to be expressed as the amount of lipocortin 1 present in ng/l0' cells.
The classically described peripheral blood leucocyte response to corticosteroid of neutrophilia, monocytopenia and lymphopenia was observed in all eight individuals between 6 0 and 240 min after corticosteroid administration.
Lipocortin 1 was generally undetected in plasma samples assayed, before and during the experiment. Table 1 summarizes the changes in lipocortin 1 levels in the various leucocyte compartments during the time course of the experiments. Individuals showed a wide range of basal levels, both on cell surfaces and intracellularly. Internal levels in both MNC and PMN were an order of magnitude higher than those on the cell surface. Administration of corticosteroid resulted in significant increases in the surface expression of lipocortin 1 from MNC isolated at 120 and 180 min. lntracellular levels were also significantly elevated at I20 min. In general, subjects with the highest resting internal MNC lipocortin 1 exhibited the largest induction by steroid. Peak concentra- tions o f lipocortin 1 within MNC occurred at 120 min in seven o f the eight individuals studied. Levels were returning towards baseline in all subjects by 240 min. PMN failed to show lipocortin 1 induction in response to steroid, both on the cell surface and internally. However, at 240 min therc was a significant fall in intracellular concentrations. No demonstrable differences occurred in any parameter for any cell type or compartment during the two control experiments in the absence of steroid (data not shown). The presented data indicate that lipocortin 1 is indeed induced in MNC in vivo in man by low dose exogenous corticosteroid. The effect is not seen in PMN. This raises the possibility that a potential deficiency of lipocortin 1 production by MNC, either in response to endogenous cortisol or exogenously administered corticosteroid, could be reflected in the degree of down regulation of an inflammatory 1.
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Production, purification and characterization of polyclonal antibodies to glutamate dehydrogenase from human liver GDH could be used in assays t o measure the levels of this enzyme in biological fluids and in immunohistochemistry. This paper describes the production, purification and characterization of polyclonal antibodies to GDH isolated from human liver. Two New Zealand white rabbits were immunized subscapularly and intramuscularly with native GDH [dissolved in 50 mM-sodium and potassium phosphate buffer, pH 7.4, in 30%) (v/v) glycerol] over a period of 5 months. For the primary immunization GDH (157 pg/0.75 ml) was emulsified with Freunds complete adjuvant (FCA) using an ultra Turrax homogenizer. The second and subsequent injections were emulsified in Freunds incomplete adjuvant (FIA). The immunization schedule is shown in Table 1 . When the titre of the antisera reached an acceptable level, at least 1 x Abbreviations used: GDH. glutamate dehydrogenase; FCA. Freunds complete adjuvant; FIA, Freunds incomplete adjuvant; ELISA. enzyme-linked immunosorbent assay; PBS, phosphatebuffered saline. dilution, the rabbits were exsanguined and killed. The blood was allowed to clot at 4°C and centrifuged at 1000 g for 15 min. The serum was removed and frozen at -20°C in aliquots.
To determine the titre of the antibodies raised. an enzymelinked immunosorbent assay (ELISA) procedure was used [6] . Dilutions from 1 x l o -' to 1 x 10-i of antiserum were used. The antibody could be detected up to dilutions of 1 x 1 0 -i in the serum from both rabbits. An antibody dilution of 1 x lo-' which gave a reading above 1.0 absorbance unit in ELISA was used routinely in ELlSA and Western blotting.
Western blotting was used to determine the specificity of both antibodies ( A and B) against different sources of mammalian GDH. Crude extracts of rat liver and rat heart were prepared by chopping the tissue into small pieces and placing them in 5 ml of phosphate-buffered saline (PBS), pH 7.4. The tissue was then homogenized in a 5 ml glass hand homogenizer. The homogenized tissue was centrifuged at 1000 g for 20 min and the supernatant was stored at 4°C. GDH from different sources was examined using native and denaturing polyacrylamide-gel electrophoresis [7] . The resulting gels were blotted according to the method of Towbin ef ul. 181. Antibody ( A ) could detect rat liver, rat heart, bovine liver and human liver GDH in both the native and denatured state. Antibody B could detect rat liver, heart, bovine and human liver GDH in the native form. However. when the enzyme was electrophoresed using the Laemmli 171 SDS/ polyacrylamide-gel electrophoresis system, antibody B could detect the human liver enzyme only. These results suggest differences in the epitopes recognized by both antisera. The amino acid sequence o f GDH is highly conserved between these species. Comparison of sequence data for the enzyme from bovine and human liver showed that only 24 of the 454 residues were different [ 9 ] . Therefore, it was surprising that small differences in epitope characteristics would be detectable using polyclonal antibodies. There have been suggestions that there may be isoenzymes of GDH [ I ] and it is conceivable that these antibodies are detecting different enzyme forms.
Purification of antibody A was achieved by affinity chromatography using bovine GDH (Sigma) coupled to Sepharose 4B (Pharmacia) according to the manufacturer's instructions. Since GDH from bovine and human liver is sen-
